Drug intelligence / Profile preview

CY006

Development stage: Preclinical
Lead developer: Shanghai Chaoyang Pharmaceutical
Modality: Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CY006 is an experimental degrader antibody conjugate (DAC) being developed by Shanghai Helioson Pharmaceutical for the potential treatment of tumors and autoimmune diseases. Utilizing a protein homeostasis platform, CY006 consists of a targeting monoclonal antibody conjugated to a degrader payload, such as a PROTAC or molecular glue. This approach aims to combine the high specificity of antibodies with the potent protein-degradation capabilities of targeted protein degraders to address previously 'undruggable' targets. The candidate is currently in the discovery or early preclinical stage of development.

Beyond the preview

Go deeper on CY006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY006.

Explore the full profile